An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun Terminal Kinase) activation

Japanese Journal of Cancer Research

Volumn 93, Issue 7, 2002, Pages 816-824

  Yoshida, Shoko ^a   Kawaguchi, Haruhiko ^a   Sato, Shigeki ^a   Ueda, Ryuzo ^a   Furukawa, Koichi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Chemotherapy; GD2; JNK; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLORING AGENT; DNA FRAGMENT; GANGLIOSIDE; GANGLIOSIDE, GD2; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; STRESS ACTIVATED PROTEIN KINASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CURCUMIN; DOXORUBICIN; ETOPOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; NAVELBINE; PACLITAXEL; PROTEIN KINASE INHIBITOR; REAGENT;

APOPTOSIS; ARTICLE; CELL CULTURE; CHEMISTRY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; IC 50; IMMUNOLOGY; LUNG TUMOR; METABOLISM; NICK END LABELING; PATHOLOGY; SMALL CELL CARCINOMA; TIME; CANCER CELL; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SMALL CELL; CISPLATIN; COLORING AGENTS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; FLOW CYTOMETRY; GANGLIOSIDES; HUMANS; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036053357     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb01324.x     Document Type: Article

References (57)

1. Gangliosides
2. The pattern of mammalian brain gangliosides. II. Evaluation of the extraction procedures, postmortem changes and the effect of formalin preservation
3. Lipid composition of human malignant melanoma tumors at various levels of malignant growth
4. Gangliosides of normal and neoplastic human melanocytes
5. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells
6. Potential ganglioside antigens associated with human gliomas
7. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas
8. Enhanced expression of GM2/GD2 synthase mRNA in human gastrointestinal cancer
9. Localization of UDP-GaINAc: NeuAc α 2,3Gal-R β1,4(GaINAc to Gal)N-acetylgalactosaminyltransferase in human stomach. Enzymatic synthesis of a fundic gland-specific ganglioside and GM2
10. Detection of GD3 ganglioside in childhood acute lymphoblastic leukemia with monoclonal antibody to GD3: Restriction to immunophenotypically defined T-cell disease
11. tax
12. High expression of ganglioside α-2,8-sialyltransferase (GD3 synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I
13. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis
14. Lipid-bound sialic acid as a tumor marker
15. Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors
16. Expression of carbohydrate antigen sialyl Le(a): A new functional prognostic factor in gastric cancer
17. Correlation of ganglioside patterns of primary brain tumors with survival
18. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry
19. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma
20. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2
21. Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival
22. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study
23. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
24. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders
25. Antibodies state a comeback in cancer treatment
26. Disialogangliosides GD2 and GD3 are involved in the attachement of human melanoma and neuroblastoma cells to extracellular matrix proteins
27. Biologic roles of gangliosides G (M3) and G (D3) in the attachment of human melanoma cells to extracellular matrix proteins
28. Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody
29. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics
30. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression
31. Ganglioside G (D2) in small cell lung cancer cell lines: Enhancement of cell proliferation and mediation of apoptosis
32. Chromatographic separation of human brain gangliosides
33. Isolation of GD3 synthase gene by expression cloning of GM3 α-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody
34. Expression cloning of rat cDNA encoding UDP-galactose:GD2 β1,3-galactosyltransferase that determines the expression of GD1b/GM1/GA1
35. Protein measurement with the Folin phenol reagent
36. Recombinant antibody constructs in cancer therapy
37. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies
38. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody
39. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
40. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
41. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
42. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptorenhanced chemosensitivity
43. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer
44. The platinum agents: A role in breast cancer treatment?
45. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer
46. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity
47. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCL) cell lines
48. Apotosis and cancer chemotherapy
49. Activation of apoptosis pathways by anticancer treatment
50. Cancer therapy and p53
51. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
52. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cisdiamminedichloroplatinum (II) in p53-deleted ovarian cancer cells
53. The stress-activated protein kinase subfamily of c-Jun kinases
54. Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation
55. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents
56. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis
57. Monoclonal antibody therapies-a 'constant' threat to cancer